secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2026-05-28T20:05:29+00:00
Accession:  0001104659-26-067474
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm appoints former FDA official Peter Pitts to Board ahead of ALS trial
-------------------------------------------------------------------------------

- Appointed Peter Pitts, former FDA Associate Commissioner, to the Board effective May 25, 2026.
- Pitts granted option for 150,000 shares; half vested immediately, half vest in six months.
- Company preparing to initiate Phase 3b ENDURANCE trial for NurOwn in ALS under FDA Special Protocol Assessment.
- Board expanded from seven to eight directors; Pitts determined independent under SEC rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926067474/0001104659-26-067474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926067474/tm2615772d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-067474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer